Curetis to Use MDx Platform for Cempra Pneumonia Drug Trial | GenomeWeb

NEW YORK (GenomeWeb News) – Curetis and Cempra today announced a collaboration for the use of Curetis' Unyvero molecular diagnostic system in Cempra's phase III trial for its oral drug for community-acquired bacterial pneumonia.

Cempra expects to enroll more than 800 patients for the trial, which will compare its solithromyrin oral formulation against a comparator drug in more than 100 clinical sites globally. Samples of sputum will be sent to Curetis for analysis with its Unyvero Solution and Unyvero P50 Pneumonia Application Cartridge.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.